Category Archives: Rafarma Pharmaceuticals Inc. RAFA

Rafarma Pharmaceuticals, Inc. (RAFA) is a Solid Ship on a Rising Sea

August 30, 2013

One investment rule of thumb is to look for a solid ship on a rising sea. In this case, the rising sea is the Russian pharmaceutical industry, driven by a need that is clearly recognized by the Russian government. The government is actively encouraging the growth of the domestic pharmaceutical industry, with specific support for selected companies to foster the growing production of both basic and innovative drugs, all in a move to reduce the country’s dependence on foreign medicines.

The efforts of the government, together with a clear market need, have pushed the overall Russian pharmaceutical industry to record growth, and it is now expected to top $10 billion by 2014, and some say as much as $60 billion by 2020, with biotech R&D playing a significant role. Various areas around the country have become focal points for this drive, and a number of U.S. and European pharmaceutical companies are either moving or building research and production facilities in Russia to take advantage of growing market opportunities and a generally supportive climate. Russia has become an especially popular place to pursue clinical trials, given its reputation for both financial support and the expediting of the trial process.

The “solid ship” in this picture is Rafarma Pharmaceuticals, relatively new but already one of the leading research companies in the Russian pharmaceutical industry. Rafarma is positioned to benefit from federal initiatives, and by 2018 the company intends to be one of the top players in the Russian pharmaceutical market, producing a range of generic and alternative basic pharmaceutical products available for sale at “mass market” prices. The company has been listed as one of the leading and most prospective projects in the modern Russian pharmaceutical and medical industry. Rafarma considers itself on track to saturate the Russian market as a European-based specialist pharmaceutical producer. The company is also securing its foothold to penetrate international markets such as Brazil and the Southeast Asian sub-continent.

For more information, visit www.Rafarma.us

Let us hear your thoughts: Rafarma Pharmaceuticals, Inc. Message Board

Rafarma Pharmaceuticals, Inc. (RAFA) Leads the Charge against Big Pharma

August 23, 2013

For years, the worldwide pharmaceutical stage has been dominated by the giant pharmaceutical companies of North America and Europe. With the exception of Japan, now a major player, medicinal drug production has been concentrated in the U.S., Germany, France, and the UK. Given a global market size approaching a trillion dollars, the pharmaceutical market represents an irresistible opportunity that is now being pursued by other parts of world. China and India represent huge markets for lower-end pharmaceuticals, and the African pharmaceutical market is approaching $30 billion. Having hundreds of millions of people dependent upon a relative handful of countries and producers has become a source of concern for many governments.

In Russia, the government has taken the situation so seriously that it has pursued a number of programs to encourage the growth of its own pharmaceutical industry. In 2010, Russia’s then-President Dmitry Medvedev called for measures to further develop the domestic pharmaceutical industry and reduce the country’s dependence on foreign medicine. The initiative was echoed a year later by Vladimir Putin. Plans now call for $39 billion in financing in support of biotechnology under the umbrella of what is called the “The Comprehensive Program for Development of Biotechnology in the Russian Federation through 2020.”

Rafarma Pharmaceuticals has been one of the big beneficiaries of this movement, with the immediate result being the construction of the most technologically advanced pharmaceutical plant in Russia. The company has since been accelerating plans to produce a variety of generic pharmaceuticals, all part of the plan to greatly reduce the retail price of the most widely used drugs, freeing the country from the stranglehold of big pharma. Rafarma has, among other agreements, already been contracted for the production of the anti-cancer drug Imatinib and the anti-tuberculosis drug Para-Aminosalicylic Acid, as well as producing its own lines. The company is also actively developing a number of research and distribution agreements.

For more information, visit www.Rafarma.com

Let us hear your thoughts: Rafarma Pharmaceuticals, Inc. Message Board

Why Rafarma Pharmacetuicals, Inc. (RAFA) is Ready to Succeed in a Multi-Billion Dollar Industry

August 16, 2013

In 2008, the Russian Government enacted a plan to reform the Russian pharmaceutical industry, heavily supporting efforts of domestic manufacturers. By 2012, a number of significant legislative acts had been been adopted and the government continues to offer initiatives, amendments, and adjustments to polish its broader strategy of modernizing the Russian pharmaceutical market.

According to research conducted by Ernst & Young (2012 survey), the volume of the Russian pharmaceutical market in 2011 grew by 12 percent vs. the year prior, outpacing global market growth of 5-7 percent. Other research forecasts that the Russian pharmaceutical market will be valued at $60 billion by 2020, representing annual growth of at least 15 percent.

Rafarma Pharmaceuticals has positioned itself to directly benefit from the government’s initiatives, recently constructing a sprawling, 270,000 square-foot manufacturing facility where the company produces generic antibiotics and specialty pharmaceutical products in addition to its own line of proprietary products that have been approved by the Ministry of Health of Russian Federation.

Rafarma anticipates being one of the leaders in the nation’s “big pharma,” leveraging its top-grade production facility and growing product portfolio to carve its path to become a major player in the international drug industry.

Julia Andryshokova, member of ZAO Rafarma’s board of directors, recently called the facility “one of the most ambitious projects in the Russian industry in recent years.”

“This facility permits us to introduce into our manufacturing practice modern scientific developments, and it permits us to improve the technology of our production constantly,” she said in a recent QualityStock interview. “Our strategy does permit us to see ourselves at the top of leaders of Russia’s pharmaceutical market.”

In line with its mission to work with the auspices of aggressive federal initiatives to fast-track the modernization of Russia’s pharmaceutical industry, Rafarma has planted itself in the right position to take advantage of broader industry growth supported by aggressive government initiative.

For more information, visit www.Rafarma.com

Let us hear your thoughts: Rafarma Pharmaceuticals, Inc. Message Board

Rafarma Pharmaceuticals, Inc. (RAFA) Roars through July with Key Achievements, Kicks-off Month of August with Same Fervor

August 9, 2013

For management of Rafarma Pharmaceuticals, July was a bustling month of business strategy. The company knocked out a handful of initiatives as it continues to grow as one of Russia’s leading pharmaceutical manufacturers.

In early July Rafarma entered into a new production contract for the manufacture of para-aminosalicylic acid (PAS), which will be marketed and distributed by OOO “Advance Trading,” a leading distributor of PAS in Russia who is responsible for roughly 20 percent of sales of PAS in the Russian market. According to pharmaceutical analysts at DSM Group, the PAS market in the Russian Federation topped $8.2 billion in 2011.

Less than two weeks later, Rafarma entered into another production agreement, this time with JSC F-Synthesis for the production of anti-cancer drug, Imatinib. In 2012, JSC reported sales of $30 million worth of Imatinib, catapulting the company to one of the Top 3 national vendors of the drug. Pharmexpert pharmaceutical business analysts estimate the market for Imatinib in Russia at slightly less than $200 million for the year 2012.

Shortly after its agreement with JSC F-Synthesis, Rafarma announced seven industry professionals as the new board of directors to the company’s operational subsidiary, ZAO Rafarma.

Rafarma wrapped up the month of July with a cooperative research and development effort with Christian Albrecht University in Kiel to develop Liposomal forms, anti-cancer, and anti-tuberculosis drugs for the creation of parenteral medications based on non-dissolvable pharmaceutical substances using encapsulation and liposomes. In addition, the entities will collaborate for the development of products with higher bioavailability through modification of biopharmaceutical characteristics. Rafarma says this is the first of several expected cooperative projects with the University.

Moving into August, Rafarma is at it again, this time announcing that in choosing Terbuny, Russia, for its world-class pharmaceutical manufacturing facility, it has attracted more biotech companies to the area. A new facility specifically devoted to dialysis research and product development has set roots near Rafarma’s plant and the two facilities plan to work in close cooperation for the development of dialysis-specific products.

With a consistent wake of advancements behind it, Rafarma looks to be on track to reach its goal of becoming one of the Top 3 players in the Russian pharmaceutical market by 2018, producing a range of generic and alternative basic pharmaceutical products available for sale at “mass market” prices.

For more information, visit www.Rafarma.com

Let us hear your thoughts: Rafarma Pharmaceuticals, Inc. Message Board

Rafarma Pharmaceuticals, Inc. (RAFA) Triggers Growth in Russian Economic Development Region, Subsequent Partnership Opportunity

August 2, 2013

The strategic selection of Terbuny, Russia, as the home for Rafarma Pharmaceuticals’ world-class manufacturing facility has resulted in more biotech companies moving into the area, and has already provided Rafarma with specialized collaboration opportunities.

A newly announced facility specifically devoted to dialysis research and product development will be located near Rafarma’s pharmaceutical plant in Terbuny in the Lipetsk region of Russia, located just a few hours south from Moscow. Rafarma and the new dialysis facility intend to work together to develop dialysis-specific products.

“Rafarma was one of the first to build and operate in Terbuny, and the company’s success looks to be the start of a new biotech hub in Russia,” Rafarma CEO Dave Anderson stated in the press release. “Rafarma is not only committed to growth as a company, but also to the development of Terbuny and its local economy and residents.”

Terbuny is part of a broader special economic development region that Russian pharmaceutical industry advocates anticipate will stimulate economic growth and jobs in the area. By constructing and maintaining its facilities in Terbuny, and staffing the plant with local residents, Rafarma is awarded specific government incentives which enhance the company’s bottom line.

From new 270,000 square-foot state-of-the-art manufacturing and distribution facility, Rafarma produces generic antibiotics and specialty pharmaceutical products in addition to its own line of proprietary products that have been approved by the Ministry of Health of Russian Federation.

For the last three years, the Russian Government has taken considerable action to accelerate the development modernization of nation’s domestic pharmaceutical industry. In line with this focus, Oleg Korolyov, governor of the Lipetsk region, praised the latest development in an article published at news.mail.ru: http://news.mail.ru/inregions/center/48/economics/14019946/

For more information, visit www.rafarma.us

Let us hear your thoughts: Rafarma Pharmaceuticals, Inc. Message Board

Rafarma Pharmaceuticals, Inc. (RAFA) and the Developing Russian Market

August 1, 2013

Between Europe and China there is another large and growing market. Russia and its 142 million consumers represent an important and still largely untapped opportunity. Russia continually vies with Saudi Arabia for the title of world’s leading oil producer, and with the U.S. for the title of top natural gas producer. The country is considered to hold the world’s greatest reserves of natural gas, and the second greatest coal reserves. It’s a top exporter of steel and aluminum, also exporting copper, iron, nickel, and many other metals and minerals.

With low unemployment and a gross domestic product of over $2.5 trillion, yet with a number of still developing sectors, Russia is drawing in foreign investment, and the Russian government is actively encouraging the growth of non-resource industries, with a special emphasis on technology. An example is the Russian pharmaceutical industry, where the government is anxious to reduce dependence upon foreign supplies for important drugs, and is encouraging the growth of pharmaceutical companies.

Rafarma Pharmaceuticals is a fast-growing pharmaceutical company in Russia that is benefitting from this encouragement. The company recently completed construction of the most technologically advanced pharmaceutical facilities in Russia, and is already producing generic antibiotics and specialty pharmaceuticals, in addition to its own line of proprietary products. Rafarma is already securing its foothold in the industry, and its marketing plans have already led to the company being considered the principle supplier to the Russian Public Health system and the Russian Army.

Rafarma Pharmaceuticals is now fully GDP compliant, and GCP and GMP standards are in their last stages of approval. The company is also working to become GLP and GAP compliant, at which time Rafarma Pharmaceuticals will be one of the only Russia-based pharmaceutical companies representing the complete cycle of the world’s top pharmaceutical standards.

For more information, visit www.rafarma.us

Let us hear your thoughts: Rafarma Pharmaceuticals, Inc. Message Board

Rafarma Pharmaceuticals, Inc. (RAFA) Enters Cooperative Effort with Christian Albrecht University

July 25, 2013

Rafarma Pharmaceuticals just announced a cooperative research and development effort with Christian Albrecht University in Kiel on the following projects:

• The development of innovative Liposomal forms, anti-cancer and anti-tuberculosis drugs with certain targeted pharmacokinetic characteristics. The objective is to create parenteral medications based on non-dissolvable pharmaceutical substances using encapsulation and liposomes.

• The development of products with higher bioavailability (thereby increasing absorption rates) through modification of biopharmaceutical characteristics. The modifications are achieved by the creation of nano-crystals, which are formed through size reduction in the gas phase, as well as through synthetic crystallization.

These are only the first of several projects Rafarma is exploring in cooperation with Christian Albrecht University.

Rafarma CEO Dave Anderson stated, “This cooperative effort creates a synergy between a top-level research university and a state-of-the-art pharmaceutical production plant, which will open up many opportunities now and in the future for both Rafarma and Christian Albrecht University.”

Newly-appointed board member and CAU faculty member, Dr. Hartwig Steckel [the Director of the Department of Pharmaceutics and Biopharmaceutics (Institute of Pharmacy) at Christian Albrecht University], commented, “This relationship is extremely exciting and I look forward to progressing rapidly with RAFARMA-CAU joint developments.”

The University of Kiel, also known as Christian Albrecht University (CAU), was formally inaugurated in 1665. During its almost 350-year existence, the Christian-Albrechts-Universität in Kiel has given impetus and set new standards in many fields, including Pharmaceutical Technology. That much is clear from its roll-call of Nobel Prize winners. Some of the many recipients of this award to have taught at Kiel were Philipp Lenard (Physics 1905), Max Planck (Physics 1918) and Otto Diels (Chemistry 1950). Over the course of its history, the CAU has developed from a regional training academy to an internationally recognized university.

For more information on Rafarma, visit www.Rafarma.com

Let us hear your thoughts: Rafarma Pharmaceuticals, Inc. Message Board

Rafarma Pharmaceuticals, Inc. (RAFA) Introduces Operational Subsidiary’s Board of Directors

July 17, 2013

Rafarma Pharmaceuticals, producer of generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products, today issued a press release announcing its operational subsidiary’s Board of Directors. Comprised of industry veterans, the well-qualified team is presented below:

Nadezhda Brusnitsina, Chairman of the Board – Former director of the MBA program for the Russian Academy of National Economy and State Service, under the President of the Russian Federation, where she was also a Professor in the Department of Project Management. Ms. Brusnitsina has a PhD in Economics and over 13 years’ experience in management.

Irina Shashkova, First Deputy to Director-General – With more than 30 years’ experience in various pharmaceutical enterprises, Ms. Shashkova provides a broad range of skills in the industry. She was awarded a certificate of excellence by the Ministry of Health of Russian Federation for her work in advancing pharmaceutical initiatives in Russia.

Andrey Sinitsin, M.D. – Dr. Sinitsin is a medical professional with over 10 years’ experience in marketing and sales of pharmaceutical products. Mr. Sinitsin has been a key contributor in growing Rafarma, particularly in the procurement of production contracts for the company.

Mikhail Nazarychev – Mr. Nazarychev’s experience and skill set are in investment and commercial banking. Mr. Nazarychev obtained his educational degrees at the Russian Federation Finance Academy where he majored in banking and finance. Mr. Nazarychev has played a key role in the financing of the company’s growth and expansion.

Tatiana Leontieva, J.D. – A graduate of Moscow University in Social law, Ms. Leontieva is a seasoned corporate professional who also has held important government positions for the Russian Federation. Ms. Leontieva was part of the team that initiated and founded ZAO Rafarma. She also holds board positions, including a chairmanship, with industry-related companies.

Hartmut Gerlof – Vice President of Textima, Germany. Mr. Gerlof brings to Rafarma a lengthy history of corporate management of large companies within the industry. Mr. Gerlof’s experience allows him to facilitate relations with the German Science and Manufacturing communities for the expansion of Rafarma’s revenue opportunities in Germany.

Professor Dr. Hartwig Steckel – Dr. Steckel is a licensed pharmacist as well as the Director of the Department of Pharmaceutics and Biopharmaceutics (Institute of Pharmacy) at Christian Albrecht University in Kiel, Germany. Dr. Steckel is also a member of the International Association for Pharmaceutical Technology (APV), the American Association for Pharmaceutical Scientists (AAPS) and the German Pharmaceutical Society (DPhG).

CEO Dave Anderson commented, “We welcome these new members and look forward to working closely with such a diverse and experienced board.”

For more information on Rafarma, visit www.Rafarma.com

Let us hear your thoughts: Rafarma Pharmaceuticals, Inc. Message Board

Rafarma Pharmaceuticals, Inc. (RAFA) Announces New Exclusive Production Contract to Produce Anti-Cancer Drug Imatinib

July 16, 2013

Rafarma Pharmaceuticals, producer of generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products, today reported the signing of a new exclusive production agreement with JSC F-Synthesis for the production of the anti-cancer drug Imatinib.

According to Pharmexpert, the leader in the Russian market for pharmaceutical business analysis, the market for Imatinib in Russia last year totaled slightly less than $200 million (USD). JSC F-Synthesis alone sold $30 million (USD) worth of Imatinib in 2012, putting the company in the top three national vendors of Imatinib.

In today’s press release, Rafarma told investors that this new contract will increase production volume while simultaneously reducing production costs, with increased sales volume and market share anticipated.

Used in the treatment of multiple cancers, Imatinib is important in the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors. The drug works as a form of targeted therapy — only cancer cells are killed through the drug’s action. In fact, Imatinib was one of the first cancer therapies to show the potential for such targeted action, and is often cited as a paradigm for research in cancer therapeutics.

For more information on Rafarma, visit www.Rafarma.com

Let us hear your thoughts: Rafarma Pharmaceuticals, Inc. Message Board

Exclusive Look at Rafarma Pharmaceuticals, Inc. (RAFA), Burgeoning Russian Pharmaceutical Industry

July 10, 2013

In a QualityStocks Production released today, Rafarma Pharmaceuticals’ management explains the company’s world class production facility, manufacturing equipment, scientific developments, and its strategy to become a leading pharmaceutical player in the Russian pharmaceutical industry.

“The target of Rafarma is providing a pharmaceutical market, domestic Russian pharmaceutical market, and foreign pharmaceutical markets with pharmaceutical products of the highest quality at affordable prices,” Julia Andryshkova, a member of the board of directors of ZAO Rafarma, says in the interview.

CEO Sergey Brunsnitsyn explains the construction, engineering, maintenance, and capabilities of the plant, as well as its overarching production goals.

“The program aims for developing of modern high-performance industrial and production basis corresponding to the GMP standards that will provide highly competitive domestic products for both internal and external markets,” he says.

The video includes interviews from several individuals on the company’s management team as well as plant employees.

To watch the entire video, visit http://videos.qualitystocks.net

For more information on Rafarma, visit www.rafarma.com

Let us hear your thoughts: Rafarma Pharmaceuticals, Inc. Message Board

Rafarma Pharmaceuticals, Inc. (RAFA) Targets Fair Share of Russia’s Rapidly Growing Pharmaceutical Market

July 8, 2013

Rafarma Pharmaceuticals constructed and now operates a 270,000-square foot multi-purpose pharmaceutical facility in Russia in direct response to the Russian Government’s plan to significantly advance the domestic pharmaceutical industry in the Russian Federation.

In a recent video interview with the QualityStocks Production team, Rafarma CEO Sergey Brunsnitsyn details the operations and qualification of the production plant, how it meets world standards in the field of pharmaceuticals and industrial construction, and the company’s strategy to secure 5 percent of market share in the Russian pharmaceuticals market by 2017.

“The strategies of the company, the professional team, the modern production facilities and our projects allow us to look forward with confidence and ensure the presence of high-quality generics and innovative medical products for our Russian and foreign consumers,” Brunsnitsyn says in the interview.

To view the entire video production visit http://videos.qualitystocks.net

For more information visit www.rafarma.com

Let us hear your thoughts: Rafarma Pharmaceuticals, Inc. Message Board

Rafarma Pharmaceuticals, Inc. (RAFA) Enters Production Agreement to Manufacture Pharmaceutical Product

Rafarma Pharmaceuticals announced that it entered into a production agreement last month to manufacture Para-Aminosalicylic Acid (PAS), which is to be marketed and distributed by OOO Advance Trading.

Rafarma aims to work with federal initiatives to fast track the modernization of Russia’s pharmaceutical industry. It produces generic antibiotics, specialty pharmaceuticals, and its own line of proprietary products, which have been approved by the Russian Federation’s Ministry of Health.

Working with Advanced Trading will allow Rafarma to increase production of PAS and to become one of the leading PAS suppliers throughout the Russian market.

As one of Russia’s leading PAS distributors, Advance Trading is currently responsible for approximately 20% of sales in the Russian market. In 2011, the PAS market in Russian Federation was over than $8.2 billion dollars, according to data provided by DSM Group (a leading pharmaceutical market analyst).

Rafarma Pharmaceuticals’ CEO, Dave Anderson, remarked, “This new contract is yet another expansion of Rafarma’s production capability, opening the door for more revenue.”

For more information, visit www.Rafarma.com

Let us hear your thoughts: Rafarma Pharmaceuticals, Inc. Message Board

QualityStocks Production Team Captures Significance of Rafarma Pharmaceuticals, Inc. (RAFA) World Class Production Facility

July 1, 2013

Rafarma Pharmaceuticals has made a significant investment in a 270,000-square-foot state-of-the-art production facility in the economic development zone in Terbuny, Lipetsk Region, south of Moscow. This sprawling, multi-profile pharmaceutical plant has the capability and space to produce all types and forms of medical drugs of various pharmacological groups.

The facility was designed to accommodate a fair share of the burgeoning Russian pharmaceutical market, which is growing in tremendous leaps and bounds following an aggressive development campaign launched by the Russian government in 2010.

Upon full production, which is expected to commence later this year, Rafarma anticipates being one of the leaders in the nation’s “big pharma.”

The QualityStocks Production team recently compiled an informative video on Rafarma, specifically highlighting the company’s facility and support the company has received from the Ministry of Industry and Trade of the Russian Federation, The Russian Ministry of Health, and The Administration of Lipetsk.

“It’s one of the most ambitious projects in Russian industry in recent years … this facility permits us to introduce into our manufacturing practice modern scientific developments, and it permits us to improve the technology of our production constantly,” Julia Andryshokova , member of ZAO Rafarma’s board of directors, says in the video. “Our strategy does permit us to see ourselves at the top of leaders of Russia’s pharmaceutical market.”

To view the entire production, visit www.qualitystocks.net/videos.php

For more information on Rafarma, visit www.rafarma.com

Let us hear your thoughts: Rafarma Pharmaceuticals, Inc. Message Board

QualityStocks Productions Releases Rafarma Pharmaceuticals, Inc. (RAFA) Video Exposing Company’s Strategic Position

June 28, 2013

The Russian pharmaceutical sector is roaring forward, estimated to reach a value of $10.7 billion by 2014 and $60 billion by 2020, fueled by the Russian Government’s initiatives to bolster the country’s domestic pharmaceutical market. Rafarma Pharmaceuticals aims to take its fair share of the market and emerge as one of the Top 3 Russian pharmaceutical companies within the next decade.

To reach this goal, Rafarma has built a new world-class 270,000 square-foot manufacturing plant in a strategic location and operated by a highly classified management team.

A recent video published by QualityStocks Productions highlights Rafarma’s position in the burgeoning industry, its stellar production facility, and how the company has contributed to the economic growth in Russia. To view the video, visit http://video.qualitystocks.net.

“The Russian Federation has expressed great interest in entering the big pharma initiative. With this initiative, Rafarma is poised and place in a location and in a way that we believe Rafarma will enter that big pharma market,” Dave Anderson, CEO of Rafarma’s USA Operations, says in the video.

Rafarma’s manufacturing facility is located in Terbuny, Lipetsk Region, Russia, positioned to raise the economic standard of the area and employ local citizens under the leadership of experienced a director and team of engineers.

Armed with skilled and trained employees, the company’s facility is comprehensive in its capabilities.

“It’s not just a manufacturing facility. It’s also developmental labs,” says Jack Brannelly, outside counsel for Rafarma. “They create their own products and patent those products here. But they also have the capacity to manufacture for other companies. They can create generic drugs.”

From its technologically advanced facility, Rafarma is positioned to modernize Russia’s domestic medical/pharmaceutical industry, leveraging the Russian government’s aggressive strategy. What differentiate Rafarma from its peers are its state-of-the art facility and industry qualifications.

“Rafarma has been given the highest qualifications in the international standards. This sets us apart from many other pharmaceutical companies and allows us to be able to provide that excellent service,” says Anderson.

For more information, visit www.rafarma.us

Let us hear your thoughts: Rafarma Pharmaceuticals, Inc. Message Board

Rafarma Pharmaceuticals, Inc. (RAFA) Management Knows the Numbers

June 21, 2013

One of the most challenging aspects of developing a new company in a mature industry is bringing together a management team that understands the key financial and legal aspects of the marketplace, people who are able to recognize ideas with actual potential and turn them into concrete money-generating realities. Rafarma Pharmaceuticals, a new and rapidly growing company in Russia that is being actively encouraged by the Russian government as a developing source for key pharmaceuticals, was founded with exactly that principle in mind.

• Dave Anderson (CEO and Director) has over 10 years professional experience in managing and operating businesses. Prior to joining the Rafarma team, Mr. Anderson worked for companies like Wells Fargo and Investors Alliance Lending as a Principal Lending Manager. Mr. Anderson started his first company at age 22. He has also started and managed his own non-profit organization helping troubled teens straighten out their lives. Mr. Anderson has degrees in International Business and Finance.

• Sergey Brusnitsin, JD, PhD (CFO and Director) came to Rafarma from the position of Vice-Chief of the Federal Revenue Service of Russia, Interregional Inspection. Mr. Brusnitsin carries both a law degree from Moscow Financial and Industrial Academy and a PhD from Moscow State Univesity of Economics, Statistics and Information Systems. Mr. Brusnitsin’s dissertation was on management of cash flows and loans in international corporations. Mr. Brusnitsin is a valuable asset for Rafarma with his tremendous expertise in international corporations, law, and finance.

• Alexander Ageev, JD (Secretary Treasurer) specializes in state-legal and financial law. Prior to joining Rafarma Pharmaceuticals, Mr. Ageev worked as a court session specialist secretary, assistant judge in the Arbitration court of Moscow, and deputy chief of the organizational-control department of the Administration of Federal services, among others. He currently is the deputy general director of legal issues and information security for CJSC “Rafarma” in addition to his role as Secretary-Treasurer of Rafarma Pharmaceuticals.

For more information, visit www.rafarma.us

Let us hear your thoughts: Rafarma Pharmaceuticals, Inc. Message Board

How Rafarma Pharmaceuticals, Inc. (RAFA) Plans to Emerge a Dominant Figure in the Billowing Russian Pharmaceutical Market

June 13, 2013

The Biotechnology Industry Organization (BIO) represents more than 1,100 biotech companies, academic institutions, state biotech centers, and related organizations in more than 30 nations. As part of its initiative to “expand the boundaries of science to benefit mankind,” the organization hosts its annual BIO International Convention, the world’s largest biotechnology industry event.

Attendees benefit from keynotes and sessions from leading policymakers, scientists, CEOs, and celebrities, and at the 2013 BIO International Convention in April, convention-goers got a taste of the booming Russian pharmaceutical market leveraged by “Pharma 2020,” the Russian government’s initiative to further develop the country’s pharmaceutical/medical industry.

“We have seen a remarkable shift in opinions about pharmaceuticals in Russia in the past few years. Pharma 2020 has already become a ubiquitous term across the world,” Sergey Tsyb, director of the Department of Chemical Industries and Bioengineering Technologies at the Russian Ministry of Industry and Trad, recently told Modern Russia.

If the progress keeps its current pace, the Russian pharmaceutical industry by 2020 (relative to the naming of the Pharma 2020 project) could be responsible for the manufacture of 50 percent of drugs in circulation, 80 percent of which would be domestically developed.

The industry is valued at roughly $21.4 billion for 2012, driven by the Russian government goal to increase innovation, medicines, and medical technology. By 2020, the market is expected to top $60 billion, and this is a figure small-cap company Rafarma Pharmaceuticals anticipates playing a large part in.

Operating from its 270,000-square-foot state-of-the-art production facility, the Russia-based multi-product pharmaceutical company is producing generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products that are approved by the Ministry of Health of Russian Federation.

Rafarma’s pharmaceutical plant has the capability and space to produce all types and forms of medical drugs of various pharmacological groups, and the company earlier this month began production of the antibiotic Ceftriaxone, which according to 2011 official statistics, had a market worth estimated at more than $51 million (USD) annually. As a participant in the Russian Federal Program for “Domestic-Produced Vital Drugs,” Rafarma said it intends to take as much as 50 percent of the Russian market for Ceftriaxone.

As awareness and support of the Russian pharmaceutical market continues to grow, Rafarma is positioned to achieve its long-term goal to be one of the Top 3 players in the Russian pharmaceutical market by 2018, armed with a sprawling multi-profile pharmaceutical plant and supported by aggressive federal initiatives.

For more information visit www.rafarma.com

Let us hear your thoughts: Rafarma Pharmaceuticals, Inc. Message Board

Rafarma Pharmaceuticals, Inc. (RAFA) Begins Production of Antibiotic Ceftriaxone, Highlights Key Industry Agreement

June 6, 2013

Rafarma Pharmaceuticals, a Russia-based manufacturing facility that produces generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products, today said it has commenced production of the antibiotic Ceftriaxone.

Ceftriaxone is for the treatment of inflammatory infections of the organs of the abdominal cavity, such as peritonitis, as well as inflammatory diseases of the gastrointestinal and bile-excreting tracts.

Rafarma points to 2011 official statistics that estimate the Ceftriaxone market in Russia at more than USD$51 million each year. As a participant in the Russian Federal Program for “Domestic-Produced Vital Drugs,” Rafarma said it plans to take as much as 50 percent of the Russian market for Ceftriaxone.

Rafarmaalso said it stands to benefit from a recent long-term distribution agreement between ZAO “SIA International” and the Russian national retail chain OAO “A5 Pharmacy Ltd.,” which provides Rafarma with a national presence in the Russian Federation retail pharmaceutical market.

“The agreements with these drug store chains and pharmaceutical supply companies moves Rafarma in a very positive direction and also shows the respect these companies have for Rafarma. I am extremely pleased that we get to work with such qualified partners that have the confidence in Rafarmato lock in long-term contracts,” Rafarma CEO David Anderson stated in the press release.

“Rafarma’s increase in production and penetration of market share becomes even more assured with the 17 national distributors we have signed to long-term agreements,” he continued. “These contracts were an integral part of Rafarma’s expansion plan and will play a vital role in the expansion of operations. Rafarma has positioned itself to become one of the five leading pharmaceutical companies in the Russian Federation.”

For more information visit www.rafarma.com

Let us hear your thoughts: Rafarma Pharmaceuticals, Inc. Message Board

Rafarma Pharmaceuticals, Inc. (RAFA) and Big Pharma

May 31, 2013

It’s almost impossible to talk about the economy and living standards without eventually getting caught up in a sometimes polarizing discussion about the high cost of healthcare. Spending for healthcare, as a percentage of GDP, has grown almost everywhere in the world, including the United States. Public resentment remains understandably high in this country as the pharmaceutical industry becomes bigger and more influential, generating a sense that the largest players are starting to depend more on marketing and lobbying than on visionary research.

If Americans are reeling under the onslaught of high drug prices, it’s a feeling shared around the world, especially in countries still struggling to build their per capita GDP to higher industrialized levels. The largest pharmaceutical companies are based in the U.S. and Europe, and countries outside that sphere have even less influence and control over prices and procedures. But basic medicines are critical to the health of every country, which has driven the Russian government to ramp up a major campaign for pharmaceutical independence.

Representative of this ongoing move is Rafarma Pharmaceuticals, a newly-built and fast-growing company in Russia that is being actively encouraged by the Russian government as a developing source for critical pharmaceuticals, independent of Big Pharma. The company has already built the most technologically advanced pharmaceutical plant in Russia, and aims to manufacture a range of generic and alternative pharmaceutical products available for sale at “mass market” prices, reduced in some cases by 30%-40% under typical import prices.

 With a target market of over 100 million people, and with strong government support to grease the wheels, the company’s prospects are impressive. They are already being considered for the role of principal supplier to the Russian Public Health system and the Russian Army.

For more information, visit www.rafarma.us.

Let us hear your thoughts: Rafarma Pharmaceuticals, Inc. Message Board

Rafarma Pharmaceuticals, Inc. (RAFA) Benefitting from World Economic Challenges

May 24, 2013

Russia, like so much of Europe, Asia, and other parts of the world, has been wrestling with slow growth. For many countries, including the U.S., the problem has been a growing debt crisis, and the associated attempts to get expenditures back in line with income. It’s a crisis often blamed on years of over-spending politicians who have gradually learned to trade fiscal responsibility for short-term political expediency. But in the case of Russia, where the debt to GDP ratio is low, the challenge has been about dealing with an over-dependency on oil and gas exports in a world suddenly flush with new resources, such as from the U.S., coupled with the ongoing challenge of restructuring inefficient economic and political institutions.

For Rafarma Pharmaceuticals, having a government under growing pressure to build economic and social infrastructure while stimulating the economy has been a major benefit. RAFA is a rapidly growing Russian-based multi-product pharmaceutical company that is being actively encouraged by the government in an effort to develop Russia’s pharmaceutical independence from western-based big pharma. To this end, the company has constructed the most technologically advanced pharmaceutical plant in Russia, with the goal of producing a range of generic and alternative pharmaceutical products available for sale at “mass market” prices for the domestic market. The plan is to dramatically reduce prices on certain pharmaceutical products by 30%-40%.

The timing is right, with Russia’s pharmaceutical industry emerging as one of the world’s fastest growing markets. RAFA’s marketing plans have already led to the company being considered the principal supplier to the Russian Public Health system and the Russian Army. The company is currently fully GDP compliant, and GCP and GMP standards are in their final stages of approval. The company is also working to become GLP and GAP compliant, at which time Rafarma Pharmaceuticals will be the only Russian-based pharmaceutical company representing the complete cycle of the world’s top pharmaceutical standards.

For more information, visit www.rafarma.us

Let us hear your thoughts: Rafarma Pharmaceuticals, Inc. Message Board

Rafarma Pharmaceuticals, Inc. (RAFA) Continues to Build Drug Pipeline

May 16, 2013

Rafarma Pharmaceuticals is one of Russia’s newest and most promising pharmaceutical companies. A company whose development and growth is being actively encouraged by the government, in a move to lessen Russian dependence upon western pharmaceutical companies for widely used pharmaceuticals, Rafarma is currently specializing in the production of generic antibiotics, but has a growing pipeline of other drugs, including proprietary products already approved.

The company expects significant near-term results with its line of current and researched pharmaceuticals, including the following group of antibiotics.

• Benzalconium Fluoride – Open randomized study of the efficacy and safety of the drug “benzalkonium fluoride, topical solution 1 %” in patients with purulent-infected wounds.
• Benzomet – Open randomized study of the efficacy and safety of the drug “benzomet, vaginal suppositories” in patients with urogenital trichomoniasis.
• Benzolete – Open randomized study of the efficacy and safety of “benzolete, lozenges for resorption – 1 mg” in patients with inflammatory diseases of the mucous membranes of the oral cavity and pharynx.
• Benzoteks – Open randomized study comparative study of the efficacy and safety of the drug “benzoteks, vaginal suppositories with benzalkonium FLUORIDE – 18.9 mg” in patients with bacterial vaginosis.

Below is a list of various Rafarma products, in order of expected sales (USD) by 2014. Rafarma also deals with many drugs for contracted production.

• Pasco ($5,910,186)
• Amoxicillin+clav-k ($5,700,175)
• Azithromycin ($4,782,939)
• Clopidogrel ($4,088,210)
• Betahistine ($3,795,417)
• Glibenclamide+Metformin ($3,463,513)
• Metoprolol ($2,911,183)
• Metformin ($2,865,075)
• Bisoprolol ($2,418,957)
• Levofloxacin ($2,338,084)
• Glycine ($2,274,287)
• Vancomycin ($1,467,387)
• Quetiapine ($1,354,435)
• Cefotaxime ($1,193,041)
• Clarithromycin ($1,015,775)
• Ciprofloxacin ($839,219)
• Ibuprofen ($749,831)
• Glimepiride ($719,375)
• Norfloxacin ($710,766)
• Glibenclamide ($653,162)
• Doxycycline ($548,019)
• Risperidone ($486,959)
• Cefuroxime ($399,884)
• Ofloxacin ($362,786)
• Amoxicillin + sulbactam ($196,700)
• Capreomycin ($192,502)
• Lomefloksatsin ($59,309)

For more information, visit www.rafarma.us

Let us hear your thoughts: Rafarma Pharmaceuticals, Inc. Message Board

Rafarma Pharmaceuticals, Inc. (RAFA) Boasts the Newest and Most Advanced Pharmaceutical Facilities in Russia

May 8, 2013

Though new, Rafarma Pharmaceuticals already holds a unique position in the pharmaceutical industry, representing the most advanced pharmaceutical operations in Russia. The company is focused on the production of generic antibiotics and specialty pharmaceuticals, with the goal of becoming one of the country’s top antibiotic producers over the next 5 years and obtaining a 5% share of the overall Russian pharmaceutical market in just 3 years. Underpinning this strategic goal is the plan to reduce prices on certain key pharmaceutical products by 30%-40%, a move that is expected to help reduce dependence upon western suppliers.

In addition Rafarma plans on developing its own in-house developed and generic pharmaceuticals, as well as identifying potential acquisition targets, including brands, trademarks, and other marketing assets. They also expect to engage in joint products with foreign pharmaceutical companies.

Initially targeted, and applied for, generic medications include the following:

• Anti-cancer drugs (5)
• Anti-microbe and infection drugs (20)
• Heart health drugs (4)
• Anti-ulcer drugs (3)
• Neuroleptics (3)
• Others (2)

Self-developed products include anti-bacterial, anti-viral, anti-infection based products, currently in clinical trials, and patented instruments for medical use (inhaler, injector). The company is working with Christian Albrecht University in Germany to develop drug and related delivery products.

Underlying these developments is the company’s stated social responsibility strategy, corresponding with the government’s goal of achieving complete independence from high-cost imported medications while maintaining top international standards.

For more information, visit www.rafarma.us

Let us hear your thoughts: Rafarma Pharmaceuticals, Inc. Message Board

Rafarma Pharmaceuticals, Inc. (RAFA) Set to Take Advantage of Large and Open Market

May 1, 2013

When Russia’s richest man recently announced the purchase of $100 million in Apple stock, it was one more dramatic indication of the financial changes, and opportunities for wealth, in one of the world’s biggest countries. With a population of over 140 million, and close ties to the 190 million people of Eastern Europe, Russia represents a major market for almost everything, but especially for critical necessities such as antibiotics and other basic drugs. In the country’s transition from a centrally planned economy to a more open free market, a number of doors have been opened.

Rafarma Pharmaceuticals, with government encouragement, is aggressively helping to build what Russia and surrounding countries in the area greatly need: a sound and comprehensive pharmaceutical industry not so dependent upon western suppliers. The recently founded company has already built and equipped a 270,000 sq. ft. pharmaceutical production and distribution facility, using the latest in technologies. It’s seen as just the beginning, with the company planning to grow rapidly and become one of the top producers of antibiotics in Russia by 2018.

But antibiotics are to be just one part of the picture for RAFA. The company’s strategy is to introduce new hi-tech pharmaceuticals on a regular basis, actively marketing in-house developed and generic pharmaceutical products. RAFA has filed and is awaiting production licenses for various anti-cancer drugs, heart related drugs, ulcer drugs, neuroleptics, and other drugs. In addition, the company has a number of anti-bacterial and anti-viral drugs of its own development, currently undergoing clinical trials. In conjunction with this, the company plans to build highly efficient sales networks, with far-reaching distributorship chains, and also plans to identify potential acquisition targets and possible joint projects with foreign pharmaceutical companies.

For more information, visit www.rafarma.us

Let us hear your thoughts: Rafarma Pharmaceuticals, Inc. Message Board

Rafarma Pharmaceuticals, Inc. (RAFA) Growing to Play a Major Role in Expanding Russian Pharmaceutical Industry

April 24, 2013

With over half of the global pharmaceutical market share being controlled by the top 20 companies, primarily American or European, together with the astronomical cost of many critical drugs, it would seem to many that Big Pharma runs the world. It’s easy to understand why the Russian government, working to transition their economy to a more competitive capitalist model, would recognize the need for a Russian-based pharmaceutical industry strong enough to be more independent of the West. This is exactly what President Medvedev has called for, offering tax relief and other economic support to encourage rapid development. The goal is the creation of a base of modern and efficient production operations that comply with GMP standards, to reduce the need of Russia to purchase certain pharmaceutical products outside of the country.

Rafarma Pharmaceutical is a new and impressive result of this initiative, established to become a key component in Russia’s burgeoning pharmaceutical industry. The company has already constructed and equipped a 270,000 square foot state-of-the-art pharmaceutical production and distribution facility in Terbuny, roughly 250 miles south of Moscow, with much room to expand. The company is now producing generic antibiotics and specialty pharmaceuticals in addition to their own line of proprietary products.

The Russian pharmaceutical market is projected to reach $60 billion by 2020, representing annual growth of at least 15%. RAFA’s target is to be one of the country’s top pharmaceutical companies, obtaining a 5% overall share of the Russian market by 2016, and to have a 20% market share of key pharmaceuticals planned for the Russian market by 2018. In conjunction with this, the goal is to reduce prices on certain pharmaceuticals by 30%-40%, with revenues approaching $317 million by 2015. The company is also building an R&D base, with the goal of introducing new pharmaceutical developments on a regular basis.

For more information, visit www.rafarma.com

Let us hear your thoughts: Rafarma Pharmaceuticals, Inc. Message Board

Rafarma Pharmaceuticals, Inc. (RAFA) Sets Sights on High Goals, Takes Aim

April 17, 2013

Russia-based Rafarma Pharmaceuticals has determined its place in the global pharmaceutical industry and has armed itself with impressive means to get its cards in the stack. The company’s initial focus is on Russia’s burgeoning domestic pharmaceutical market.

The Russian pharmaceutical sector is on track to reach a value of $10.7 billion by 2014, $60 billion by 2020 – opportunity is there for the taking. As the Russian Government enforces measures to bolster Russia’s domestic pharmaceutical market, Rafarma’s aim is to take advantage of government-backed initiatives and emerge as one of the Top 3 Russian pharmaceutical companies within the next decade.

A goal of this caliber takes some heavy artillery, something much more than a business strategy that looks good on paper. To execute its mission, the company has built a new world-class 270,000 square-foot manufacturing plant hunkered on company-owned land, protecting it from land lock in the event of future expansion.

Located in Terbuny, Russia, the multi-profile pharmaceutical plant has the capability of producing all types and forms of medical drugs. The facility is supported by the government of Lipetsk region of Russia, Ministry of Health of Russian Federation, and the Ministry of Industry and Trade of Russian Federation, which listed Rafarma as one of the leading and most prospective projects in the modern Russian pharmaceutical and medical industry.

After investing considerable time and capital into its vast pharmaceutical plant, Rafarma anticipates running at full-throttle by this summer, producing generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products that are approved by the Ministry of Health of Russian Federation.

For more information, visit www.rafarma.com

Let us hear your thoughts: Rafarma Pharmaceuticals, Inc. Message Board

Rafarma Pharmaceuticals, Inc. (RAFA) Engages QualityStocks Investor Relations Services

April 10, 2013

Rafarma Pharmaceuticals announced earlier today that they have agreed with QualityStocks to be featured in The Small Cap QualityStocks Daily Newsletter, QualityStocks Daily Blogs, and Message Boards. QualityStocks, based in Scottsdale, Arizona, is a free service that collates data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts.

Rafarma owns and operates a multi-profile pharmaceutical plant that is able to produce all types and forms of medical drugs in various pharmacological groups. The plant was constructed in the territory of a special industrial economic zone in Terbuny of the Lipetsk region of Russia. The project was initiated by the Zdorovie Foundation and is considered one of the grandest projects of the Russian medical industry in the last few years.

Michael McCarthy, Managing Director of QualityStocks, stated, “We have conducted extensive due diligence and are very excited to inform the investment community of Rafarma’s corporate strategy and ongoing progress. Last month our team traveled over 6,000 miles to visit the company’s 270,000 square-foot plant and take on-site video footage. We will be releasing a series of high-definition videos that fully encapsulate Rafarma’s state-of-the art manufacturing facility and relay its legitimacy, opportunity, and enormity in the best way possible.”

The first video produced by QualityStocks can be viewed at http://Video.QualityStocks.net.

QualityStocks has also put together a detailed, 10-page investor kit as well as a 34-slide presentation, both of which can be found at http://RAFA.QualityStocks.net.

Dave Anderson, CEO of Rafarma Pharmaceuticals, stated, “RAFA has a unique and solid business foundation, and appreciates the opportunity to sponsor the QualityStocks Newsletter, Video and Blogs. QualityStocks is providing a much needed service in the micro-cap and small-cap markets.”

For more information, visit www.Rafarma.com

Let us hear your thoughts: Rafarma Pharmaceuticals, Inc. Message Board

Archives

Select A Month
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Search

    Categories

    Select A Category
  • 21st Century Holding Company TCHC (1)
  • 5BARz International Inc. BARZ (12)
  • 5G Wireless Communications Inc. FGWC (8)
  • 92 Resources Corp. RGDCF (15)
  • A.P. Pharma Inc. APPA (3)
  • Abazias Inc. ABZA (2)
  • ABcann Global Corp. ABCCF (21)
  • ABV Gold ABVG (11)
  • ACME Sports & Entertainment Inc. ASEN (2)
  • Adaptive Medias Inc. ADTM (6)
  • Advanced ID Corp. AIDO (5)
  • Advanced Medical Isotope Corp. ADMD (10)
  • Advanced Resources Group Ltd. AVRG (3)
  • Advanced Viral Research Corp. ADVR (9)
  • Advanced Visual Systems Inc. AVSC (10)
  • Advanced Voice Recognition Systems Inc. AVOI (11)
  • Advanced Wound Technologies Inc. AWTM (4)
  • Advaxis Inc. ADXS (2)
  • Agora Holdings Inc. AGHI (33)
  • Ahead of the Bulls (1)
  • AISystems, Inc. ASYI (11)
  • Aladdin Trading & Company ADTD (29)
  • Algae Dynamics Corp. ADYNF (31)
  • All American Gold Corp AAGC (13)
  • All Asia Licensing Inc. AASI (1)
  • ALL Fuels & Energy Company AFSE (49)
  • All Grade Mining Inc. HYII (3)
  • All Penny Stocks (3)
  • Allarae Healthcare Inc. ALHI (5)
  • Alliance Creative Group ACGX) (15)
  • Alliance Recovery Corp. ARVY (34)
  • Alltemp, Inc. LTMP (1)
  • AlphaTrade.com APTD (2)
  • Alpine TLI Group Inc. APGR (7)
  • ALR Technologies Inc. ALRT (9)
  • Alternative Construction Technologies Inc. ACCY (10)
  • Alternative Energy Development Corp. ADEC (1)
  • Alternative Fuel Technology Inc. AFTC (1)
  • Alternet Systems Inc. ALYI (47)
  • AM Oil Resources & Technology Inc. AMOR (8)
  • Amarin Corp. AMRN (2)
  • Amaru Inc. AMRU (2)
  • Amerex Group, Inc AEXG (16)
  • American Capital Partners Inc. APRJ (1)
  • American Fiber Green Products Inc. AFBG (1)
  • American Oriental Bioengineering Inc. AOB (3)
  • American Racing Capital Inc. AMRA (2)
  • American Software (2)
  • Amgen Inc. AMGN (2)
  • AmMex Gold Mining Corp. AMXG (2)
  • Ampex Corp AMPX (1)
  • Andover Medical Inc. ADOV (2)
  • Angstrom Microsystems Inc. AGMS (46)
  • Apolo Gold and Energy Inc. APLL (1)
  • Apple Inc. AAPL (13)
  • AppSwarm, Inc. SWRM (25)
  • Aquasil International Inc. AQUS (3)
  • Armco Metals Holdings Inc. AMCO (36)
  • AspenBio Pharma APPY (1)
  • Assured Pharmacy Inc. APHY (1)
  • Asta Funding Inc. ASFI (2)
  • Atlantic Energy Solutions Inc. AESO (1)
  • ATSI Communications Inc. ATSX (1)
  • Augme Technologies Inc. AUGT (70)
  • Auric Mining Corp. AUMY (3)
  • Automated Vending Technologies Inc. AVTC (3)
  • Automotive Company GNAU (11)
  • AV1 Group, Inc. AVOP (5)
  • Avalon Oil and Gas Inc. AOGN (16)
  • Avant Diagnostics Inc. AVDX (29)
  • Avatar Systems Inc. AVSY (3)
  • Axiom Management Inc. AXMA (3)
  • Axis Technologies Inc. AXTG (2)
  • B2Digital Inc. BTOD (18)
  • Balatia Airlines BLTA (2)
  • Bald Eagle Energy Inc. BEEI (18)
  • Banjo & Matilda Inc. BANJ (8)
  • Barchart.com (4)
  • Beacon Enterprise Solutions Group BEAC (47)
  • Beacon Equity Research (552)
  • Beijing Med-Pharm Corp. BGJP (2)
  • Bergamo Acquisition Corp. BGMO (15)
  • Big Tree Group Inc. BIGG (36)
  • Bio-Clean International Inc. BCLE (1)
  • Bio-Matrix Scientific Group Inc. BMSN (1)
  • BioCentric Energy Holdings Inc. BEHL (1)
  • Biomagnetics Diagnostics Corp. BMGP (3)
  • bioMETRX Inc. BMRX (1)
  • Bionic Products Corp. BNPD (4)
  • Biophan Technologies Inc. BIPH (1)
  • BioSolar Inc. BSRC (22)
  • Biotech Holdings Ltd. BIOHF (3)
  • BizRocket.com Inc. BZRT (9)
  • Black Diamond Brands Corp. BDMHF (1)
  • Blue Diamond Ventures Inc. BLDV (1)
  • Blue Moon Zinc Corp. BMOOF (8)
  • Blue Water Global Group Inc. BLUU (7)
  • Blugrass Energy Inc. BLUG (4)
  • Bollente Companies, Inc. BOLC (7)
  • BoonMarket.com (1)
  • Boreal Water Collection Inc. BRWC (23)
  • Boston Therapeutics Inc. BTHE (20)
  • Bridgetech Holdings International Inc. BGTH (1)
  • Brighton Oil & Gas Inc. BROG (8)
  • Britannia Mining Inc. BMIN (14)
  • Brite Strike Tactical Illumination Products, Inc. BSTI (41)
  • Brookside Technology Holdings Corp BKSD (2)
  • Bullzi Security Inc. BLLZ (3)
  • BWI Holdings Inc. BWIH (165)
  • Cache Elite Inc. ILUS (9)
  • Cal-Bay International Inc. CBYI (6)
  • Callisto Pharmaceuticals, Inc. (1)
  • Calpian Inc. CLPI (27)
  • CAMAC Energy Inc. CAK (2)
  • Canam Energy Inc. CNGJ (10)
  • CanAm Uranium Corp. CAUI (58)
  • Cannabics Pharmaceuticals Inc. CNBX (14)
  • Capital City Energy Group Inc. CETG (18)
  • Car Monkeys Group CKMY (15)
  • Carbon Sciences Inc. CABN (21)
  • CardioVascular BioTherapeutics Inc. CVBT (5)
  • Cardium Therapeutics Inc. CXM (44)
  • Carl Data Solutions Inc. CDTAF (5)
  • Cascade Technologies Inc. CSDT (2)
  • Cascadia Investment Inc. CDIN (4)
  • Casey Corp. CCPR (1)
  • Cashcow Magazine (4)
  • Cavico Corp. CVIC (3)
  • CD International Enterprises, Inc. CDII (48)
  • CDC Corp. CHINA (4)
  • CelebDirect Inc. CELI (3)
  • Cellceutix Corp. CTIX (18)
  • CellCyte Genetics Corp. CCYG (3)
  • Century Group, Inc. CEYG (1)
  • CEOcast (184)
  • CepTor Corp. CEPO (1)
  • Cereplast Inc. CERP (9)
  • Chancery Resources Inc. CCRY (3)
  • Changing Times Vitamins Inc. SGTB (12)
  • CHDT Corp. CHDO (5)
  • Cherubim Interests Inc. CHIT (36)
  • China 3C Group CHCG (13)
  • China America Holdings Inc. CAAH (8)
  • China Direct Inc. CDS (4)
  • China Education Alliance Inc. CEUA (4)
  • China Energy Recovery Inc. CGYV (12)
  • China Growth Development Inc. CGDI (2)
  • China Health Management Corp CNHC (7)
  • China Health Resource Inc. CHRI (14)
  • China INSOnline Corp. CHIO (1)
  • China Jiangsu Golden Horse Steel Ball Inc. CJGH (3)
  • China Logistics Group Inc. CHLO (11)
  • China Media Group Corp. CHMD (2)
  • China Medicine Corporation CHME (5)
  • China Nuvo Solar Energy Inc. CNUV (3)
  • China Organic Agriculture Inc. CNOA (11)
  • China Petroleum and Chemical Corp. SNP (2)
  • China Voice Holding Corp. CHVC (47)
  • China Wind Systems Inc. CWSI (6)
  • China Wireless Communications Inc. CWLC (4)
  • China Yongxin Pharmaceuticals Inc. CYXN (5)
  • China YouTV Corp. CYTV (1)
  • ChinaTel Group Inc. CHTL (1)
  • Chineseinvestors.com, Inc. CIIX (79)
  • ChromaDex Corp. CDXC (3)
  • City Capital Corp. CTCC (2)
  • Cityside Tickets CIST (21)
  • CleanTech BioFuels Inc. CLTH (10)
  • Cleantech Transit Inc. CLNO (3)
  • Clearly Canadian Beverage Corp. CCBEF (13)
  • Cleartronic Inc. CLRI (52)
  • Clenergen Corp. CRGE (37)
  • CMG Holdings Inc. CMGO (2)
  • Coastal Integrated Services Inc. COLV (13)
  • Coil Tubing Technology Inc. CTBG (1)
  • Colorado Goldfields Inc. CGFI (5)
  • Colt Resources Inc. COLTF (13)
  • Columbia River Resources Inc. CRVR (1)
  • CoMedia Corp. CMTN (1)
  • CommercePlanet Inc. CPNE (4)
  • Compress Technologies Inc. CTLG (17)
  • Conforce International Inc. CFRI (2)
  • Connect-A-Jet.com CAJT (9)
  • Cono Italiano Inc. CNOZ (12)
  • Consorteum Holdings, Inc. CSRH (160)
  • ContentChecked Holdings Inc. CNCK (60)
  • Continental Fuels Inc. CFUL (2)
  • Converde Energy USA Inc. XFUL (12)
  • Convergence Technology Group Inc. CNVC (7)
  • Copper King Mining Corp. CPRK (2)
  • Cord Blood America Inc. CBAI (102)
  • Crdentia Corp CRDT (12)
  • Creative Vistas Inc. CVAS (2)
  • Crystal International Travel Group Inc. CINT (4)
  • Cubic Energy Inc. QBC (2)
  • Cybermesh International Corp. CYTL (1)
  • Cyclone Power Technologies Inc. CYPW (9)
  • CYIOS Corp. CYIO (1)
  • Daily Views (13)
  • Dakshidin Corp. DKSC (5)
  • Data Call Technologies Inc. DCLT (25)
  • Daulton Capital Corp. DUCP (26)
  • Davi Skin Inc. DAVN (1)
  • Debt Resolve Inc. DRV (2)
  • Debut Broadcasting Corporation Inc. DBTB (1)
  • Deep Blue Marine Inc. DPBM (6)
  • Deep Down Inc. DPDW (15)
  • Deer Valley Corp. DVLY (2)
  • Defense Solutions Inc. DFSH (3)
  • Delta Mining and Exploration Corp. DMXC (1)
  • Dermisonics Inc. DMSI (1)
  • Destination Television Inc. DSTV (17)
  • Dhanoa Minerals Ltd. DHNA (4)
  • DigitalPost Interactive Inc. DGLP (8)
  • Document Capture Technologies Inc. DCMT (3)
  • DoMark International Inc. DOMK (29)
  • Dominovas Energy Corp. DNRG (73)
  • Dragon Capital Group Corp. DRGV (11)
  • Dragon International Group Corp. DRGG (2)
  • Duma Energy Corp. DUMA (20)
  • Duska Therapeutics Inc. DSKA (1)
  • Dutton Associates (88)
  • DXP Enterprises Inc. DXPE (4)
  • Dynamic Media Holdings Inc. DYMH (6)
  • Dynamic Response Group Inc. DRGP (6)
  • Dynasty Limousine Inc. DNYS (19)
  • Earth Dragon Resources Inc. EARH (10)
  • Eastbridge Investment Group Corp. EBIG (1)
  • Ebenefits Direct, Inc. EBFD (21)
  • eCareer Holdings Inc. ECHI (9)
  • Echo Therapeutics Inc. ECTE (5)
  • EcoloCap Solutions Inc. ECOS (2)
  • Ecologic Transportation Inc. EGCT (11)
  • Ecosciences Inc. ECEZ (1)
  • Ecotality, Inc. ECTY (67)
  • eCrypt Technologies Inc. ECRY (79)
  • EdgeTech International Inc. EGIL (6)
  • eDoorways Corp. EDWY (183)
  • EFoodSafety.com Inc. EFSF (4)
  • EFuel EFN Corp. EFUL (1)
  • EGPI Firecreek Inc. EFIR (1)
  • Elephant Talk Communications Corp. ETAK (8)
  • Elephant Talk Communications Inc. ETAK (2)
  • Elleipsis Global Travel Solutions Inc. EGTS (3)
  • Elray Resources Inc. ELRA (11)
  • Elron Electronic Industries Ltd. ELRN (1)
  • Emerging Media Holdings Inc. EMDH (22)
  • Empire Energy Corporation International EEGC (3)
  • Endeavor Explorations Inc. EAVR (7)
  • Endeavour Silver Corp. EXK (3)
  • Endevco Inc. EDVC (2)
  • Energtek Inc. EGTK (61)
  • Enherent Corp. ENHT (2)
  • EnterConnect Inc. ECNI (5)
  • Enterprise Oilfield Group Inc. E.TO (13)
  • EnXnet Inc. EXNT (1)
  • Epazz, Inc. EPAZ (28)
  • Equity Stock Analysis (1)
  • ER Urgent Care Holdings Inc. ERUC (6)
  • ERF Wireless Inc. ERFB (15)
  • Essential Innovations Technology Corp. ESIV (2)
  • Etelcharge.com Inc. ETLC (3)
  • Ethema Health Corporation GRST (7)
  • Euoko Group Inc. EUOK (2)
  • EV Innovations Inc. EVII (189)
  • EV Transportation Inc. EVTP (7)
  • EVIO, Inc. EVIO (12)
  • Exchange Media Corp. EXMD (9)
  • Exeter Resource Corp. XRA (2)
  • eXp World Holdings, Inc. EXPI (81)
  • Expert Group Inc. EXPT (5)
  • ExpressIR Inc. (1)
  • Extreme Motorsports of California, Inc. EMOC (26)
  • ezBanc-A Stocklender's Journal (6)
  • Falcon Crest Energy FCEN (75)
  • Falcon Ridge Development Inc. FCNR (2)
  • Famous Uncle Als Hot Dogs & Grille Inc FDOG (10)
  • Fastfunds Financial Corp. FFFC (17)
  • Financial Media Group, Inc. FNGP (26)
  • Financial Services Exchange FSE (1)
  • First Cobalt Corp. FTSSF (16)
  • First Titan Corp. FTTN (45)
  • FlexWeek Inc. FXWK (11)
  • FluoroPharma Medical Inc. FPMI (46)
  • Foldera, Inc. FDRA (11)
  • Force Energy Corp. FORC (5)
  • FormCap Corp. FRMC (29)
  • Fortune Market Media Inc. FTMM (5)
  • Franklin Mining Inc. FMNJ (1)
  • Freedom Leaf Inc. FRLF (12)
  • Fresh Harvest Products Inc. FRHV (7)
  • Fresh Promise Foods Inc. FPFI (12)
  • Freshstart Properties Inc. FSPP (1)
  • FrogAds Inc. FROG (6)
  • Frozen Food Gift Group Inc. FROZ (5)
  • Fund.com, Inc. FNDM (56)
  • Fushi Copperweld Inc. FSIN (2)
  • GainClients Inc. GCLT (9)
  • Galenfeha Inc. GLFH (28)
  • Gastar Exploration Ltd. GST (2)
  • Gemini Explorations Inc. GXPI (12)
  • Gen2media Corp. GTWO (2)
  • General Environmental Management Inc. GEVI (56)
  • General Metals Inc. GNMT (1)
  • General Steel Holdings Inc. GSI (3)
  • GeoBio Energy Inc. GBOE (1)
  • GeoEye Inc. GEOY (4)
  • GeoPharma Inc GORX (1)
  • Giggles N’ Hugs Inc. GIGL (90)
  • Global Alumina Corp. GLA.U (1)
  • Global General Technologies Inc. GLGT (1)
  • Global Payout Inc. GOHE (70)
  • Global Realty Development Corp. GRLY (10)
  • Global Resource Corporation GBRC (48)
  • Global Roaming Distribution Inc. GRDB (34)
  • GlobalWise Investments Inc. GWIV (129)
  • GNCC Capital Inc. GNCP (24)
  • Golden West Brewing Company Inc. GWBC (3)
  • GoldSpring Inc. GSPG (4)
  • Google, Inc. GOOG (8)
  • GotStocks.net (1)
  • Grandview Gold Inc. GVGDF (2)
  • Gray Publishing & Media, Inc. GPMIJ (15)
  • Graystone Park Enterprises Inc. GPKE (7)
  • Great Plains Holdings Inc. GTPH (28)
  • Green Earth Technologies GETG (1)
  • Green Star Alternative Energy Inc. GSAE (2)
  • Green Star Products Inc. GSPI (2)
  • Green Technology Solutions Inc. (GTSO) (19)
  • Greenbelt Resources Corp. GRCO (1)
  • Greenchek Technology Inc. GCHK (18)
  • Greenkraft, Inc. GKIT (18)
  • Greenstone Holdings Inc. GSHN (2)
  • GREM USA GRMU (2)
  • Grey Cloak Tech, Inc. GRCK (16)
  • GRILLiT Inc. GRLT (8)
  • Growblox Sciences Inc. GBLX (24)
  • GT Legend Automotive Holdings Inc. GTLA (2)
  • GTX Corp GTXO (49)
  • Gulf Western Petroleum Corp. GWPC (3)
  • GWS Technologies Inc. GWSC (4)
  • Halcyon Jets Holdings Inc. HJHO (15)
  • Halitron Inc. HAON (11)
  • Hanover Financial Services (17)
  • Harbin Electric Inc. HRBN (2)
  • Harvey Electronics Inc. HRVE (1)
  • Hasco Medical Inc. HASC (7)
  • Hathway Corp. HWYI (1)
  • HeadsUp Entertainment International Inc. HDUP (3)
  • Healthnostics Inc. HNSO (1)
  • HealthSonix Inc. HSXI (1)
  • HealthSport Inc. HSPO (14)
  • Heartland Inc. HTLG (1)
  • Heartland Oil and Gas Corp. HTOG (7)
  • Hemis Corporation HMSO (19)
  • Hemisphere Gold Inc. HPGI (1)
  • Hemp Inc. HEMP (25)
  • Hendrx Corp. HDRX (1)
  • Hi-Shear Technology Corp. HSR (3)
  • HighCom Global Security Inc. HCGS (19)
  • HII Technologies Inc. HIIT (8)
  • Holloman Energy Corp. HENC (2)
  • Holmes Osborne (6)
  • Hologic Inc. HOLX (4)
  • Home Shopping Latino Inc. HSPG (8)
  • Hong Kong Highpower Technology Inc. HPJ (2)
  • HotOTC (61)
  • HotStockChat (3)
  • HotStockMarket (HSM) (3)
  • HST Global Inc. HSTC (11)
  • Hunt Gold Corp. HGLC (32)
  • HWI Global Inc. HWIC (3)
  • Hydrogen Corp. HYDG (1)
  • i-Level Media Group Inc. ILVL (3)
  • i2 Telecom International Inc. ITUI (7)
  • iB3 Networks Inc. IBNW (1)
  • IceWEB Inc. IWEB (5)
  • ICP Solar Technologies Inc. ICPR (3)
  • IDGLOBAL Corp. IDGJ (2)
  • IDO Security Inc. IDOI (22)
  • IFAN Financial Inc. IFAN (34)
  • iGambit, Inc. IGMB (5)
  • Imaging3 Inc. IMGG (2)
  • ImaRx Therapeutics Inc. IMRX (2)
  • Immune Therapeutics Inc. IMUN (11)
  • Impact E-Solutions Corp. IESO (1)
  • Imperial Petroleum Inc. IPMN (10)
  • Inca Designs Inc. IDGI.PK (4)
  • Independent Film Development Corp. IFLM (1)
  • Index Oil and Gas Inc. IXOG.OB (5)
  • India Globalization Capital, Inc. IGC (21)
  • Industrial Biotechnology Corp. IBOT (1)
  • Infinite Group Inc. IMCI (48)
  • Inform Worldwide Holdings, Inc. IWWI (27)
  • InMed Pharmaceuticals, Inc. IMLFF (36)
  • Intec LTD ICLJY (1)
  • IntegraMed America Inc INMD (1)
  • Intelecom Inc. IECM (3)
  • Intelimax Media Inc. IXMD (31)
  • Intelligent Highway Solutions Inc. IHSI (6)
  • Intercept Energy Services Inc. IESCF (7)
  • Interleukin Genetics Inc. ILI (1)
  • International Barrier Technology Inc IBTGF (1)
  • International Consolidated Companies Inc. INCC (2)
  • International Stem Cell Corp. ISCO (226)
  • Inventergy Global Inc. INVT (15)
  • Investor Village (9)
  • Investors Business Daily (4)
  • InvestorsProfs (1)
  • InvestSource (11)
  • IPOs (8)
  • IR Biosciences Holdings Inc IRBS (3)
  • Isonics Corp. ISON (1)
  • ItsAboutFinance (2)
  • JC Data Solutions Inc. JCDS (4)
  • Joytoto USA Inc. JYTO (14)
  • JZZ Technologies Inc. JZZI (3)
  • KAL Energy Inc. KALG (3)
  • Kallo Inc. KALO (43)
  • Kandi Technologies Corp. KNDI (3)
  • KCM Holding Corp. KCMH (3)
  • Kingslake Energy Inc. KGLJ (2)
  • Klondex Mines Ltd. KLNDF (1)
  • Knobias KNBS (5)
  • Kootenay Zinc Corp. KTNNF (12)
  • Kraig Biocraft Laboratories Inc. KBLB (88)
  • L&L International Holdings Inc. LLFH (2)
  • Laguna Blends Inc. LAGBF (53)
  • Lantis Laser Inc. LLSR (5)
  • Last Mile Logistics Group LMLG (4)
  • Latitude 360 Inc. LATX (21)
  • LD Holdings Inc. LDHL (14)
  • Legacy Holdings Inc. LGYH (1)
  • Legacy Ventures International Inc. LGYV (24)
  • Legend Media Inc. LEGE (4)
  • Lexaria Bioscience Corp. LXRP (42)
  • Lifespan Inc. LSPN (1)
  • Lime Energy Corp. LIME (3)
  • Lingo Media Corp. LMDCF (18)
  • Linkwell Corporation LWLL (4)
  • Liquor Group Wholesale Inc. LIQR (22)
  • Loans4Less.com Inc. LFLS (47)
  • LOGIC Devices Inc. LOGC (1)
  • Logility Inc. LGTY (1)
  • LoJack Corp LOJN (3)
  • Longhai Steel Inc. LGHS (10)
  • LottoGopher Holdings Inc. LTTGF (24)
  • Lotus Pharmaceuticals Inc. LTUS (1)
  • Low Carbon Technologies (LWCTF) (3)
  • Lucas Energy, Inc. LEI (17)
  • Mabwe Minerals Inc. MBMI (56)
  • Macquarie Infrastructure Company MIC (5)
  • Maine and Maritime Corp. MMA (1)
  • Majic Wheels Corp. MJWL (6)
  • Makeup Inc. MAKU (2)
  • Mammoth Energy Group Inc. MMTE (5)
  • Mantra Venture Group Ltd. MVTG (10)
  • Marijuana Company of America, Inc. MCOA (15)
  • Mariner’s Choice International Inc. MCII (2)
  • Martin Nutraceuticals MNIU (11)
  • Material Technologies Inc. MTCH (44)
  • Max Media Group Inc. MXMI (9)
  • Max Sound Corp. MAXD (30)
  • MC Endeavors Inc. MSMY (2)
  • MedeFile International Inc. MDFI (46)
  • MediaG3 Inc. MDGC (1)
  • Medical Cannabis Payment Solutions (REFG) (2)
  • Medical Cannabis Payment Solutions REFG (3)
  • Medical Innovation Holdings, Inc. MIHI (10)
  • Medical Transcription Billing Corp. MTBC (13)
  • Medina International Holdings Inc. MIHI (3)
  • Medisafe 1 Technologies Corp. MFTH (3)
  • Medivisor Inc. MVSR (1)
  • Mega Media Group, Inc. MMDA (30)
  • MegaWest Energy Corporation MGWSF (2)
  • Memry Corp. MRY (2)
  • Metro One Development Inc. MODI (2)
  • Mexico Energy Corp. MXC (1)
  • MGX Minerals, Inc. MGXMF (19)
  • Micro Identification Technologies Inc. MMTC (44)
  • MicrocapMoney (2)
  • Microsoft Corporation MSFT (4)
  • Midway Gold Corp. MDW (1)
  • Military Resale Group MYRL (19)
  • Minco Silver Corp. MSV.TO (1)
  • Mindpix Corp. MNDP (1)
  • MIP Solutions Inc. MSOL (7)
  • MIT Holding MITD (36)
  • MitoPharm Corp. MTPH (1)
  • Mizati Luxury Alloy Wheels, Inc. MZTI (14)
  • Mobile Entertainment Inc. MBEI (1)
  • Mobile Lads Corp. MOBO (43)
  • Momentous Entertainment Group Inc. MMEG (19)
  • Monaker Group Inc. MKGI (48)
  • Money4Gold Holdings Inc. MFGD (3)
  • MortgageBrokers.com Holdings Inc. MBKR (2)
  • Mosquito Consolidated Gold Mines Limited MSQ.V (1)
  • Moxian Inc. MOXC (62)
  • mPhase Technologies Inc. XDSL (12)
  • MSE Enviro-Tech Corp. MEVT (4)
  • Muscle Flex Inc. MFLI (55)
  • MusclePharm Corp. MSLP (23)
  • Mvive Inc. MVIV (22)
  • My Automated Advisor (4)
  • MyECheck Inc. MYEC (99)
  • MyStaru.com Inc. MYST (1)
  • Nanogen Inc. NGEN (2)
  • Nanometrics Inc. NANO (1)
  • NanoSensors Inc. NNSR (1)
  • NanoTech Entertainment Inc. NTEK (30)
  • Napster, Inc. NAPS (5)
  • National Automation Services Inc. NASV (67)
  • National Coal Corp. NCOC (2)
  • National Waste Management Holdings Inc. NWMH (24)
  • Naturally Iowa Inc. NLIA (2)
  • NavStar Technologies Inc. NVSR (16)
  • nCoat Inc NCOA (8)
  • Neah Power Systems NPWZ (14)
  • Neohydro Technologies Corp. NHYT (4)
  • Neoprobe Corp. NEOP (6)
  • NeoStem Inc. NBS (6)
  • Net Element Inc. NETE (19)
  • NetSol Technologies Inc NTWK (64)
  • Neurobiological Technologies Inc. NTII (3)
  • NeuroMama Ltd. NERO (15)
  • Neutra Corp. NTRR (37)
  • New Asia Gold Corp. NWAG (1)
  • New Generation Biofuel Holdings Inc. GNB (3)
  • NewMarket China Inc. NMCH (7)
  • NewMarket Technology Inc. NMKT (7)
  • Newport Digital Technologies Inc. NPDT (61)
  • Nexia Holdings Inc. NXHD (51)
  • NexMed Inc. NEXM (8)
  • NeXplore Corp. NXPC (4)
  • Next One Interactive Inc. NXOI (7)
  • NextGen Bioscience Inc. NXGB (1)
  • NextPhase Wireless Inc. NPHS (1)
  • Nexus Enterprise Solutions Inc. NXES (30)
  • NF Energy Saving Corp. of America NFES (1)
  • Nhale Inc. NHLE (18)
  • Nilam Resources Inc. NILR (4)
  • Nitro Petroleum Inc. NTRO (5)
  • North Bay Resources Inc. NBRI (10)
  • NuTech Inc. NTCI (1)
  • Nutra Pharma Corp. NPHC (21)
  • NutraNomics Inc. NNRX (30)
  • NuVim Inc. NUVM (1)
  • NVIDIA Corp. NVDA (1)
  • NXGen Holdings Inc. NXGH (1)
  • Oakridge Global Energy Solutions Inc. OGES (63)
  • Obee's Franchise Systems Inc. OBFM (1)
  • OBJ Enterprises Inc. OBJE (27)
  • Odyne Corporation ODYC (15)
  • Omega Commercial Finance Corp. OCFN (2)
  • OmniaLuo Inc. OLUO (1)
  • Omnicity Corp. OMCY (26)
  • Omninet Media.Com, Inc. ONMC (5)
  • On The Go Healthcare Inc. MODI (13)
  • On the Move Systems Inc. OMVS (102)
  • Oncolin Therapeutics Inc. OCOL (1)
  • One Step Vending Corp. KOSK (2)
  • One World Holdings Inc. OWOO (61)
  • Ones to Watch (1,353)
  • Onstream Media Corp. ONSM (5)
  • Onteco Corp. ONTC (4)
  • Open Energy Corp. OEGY (4)
  • Optical Systems Inc. OPSY (2)
  • Oramed Pharmaceuticals Inc. ORMP (2)
  • Organic Alliance Inc. ORGC (2)
  • ORHub, Inc. ORHB (27)
  • OTCPicks.com (82)
  • OtcStockExchange (5)
  • OurPet's Company OPCO (78)
  • OxySure Systems Inc. OXYS (23)
  • P2 Solar Inc. PTOS (24)
  • Pacific Gold Corp. PCFG (3)
  • Pamplona Picks (1)
  • Pan Global Corp. PGLO (82)
  • PanGenex Corp. PGCX (3)
  • Paramount Gold and Silver Corp. PZG (3)
  • Patient Access Solutions Inc. PASO (7)
  • Patriot Energy Corp. dba TelTeck Solutions Inc PGYC.PK (11)
  • Patriot One Technologies, Inc. PTOTF (25)
  • Patriot Scientific Corp. PTSC (6)
  • Peace Arch Entertainment Group Inc. PAE (1)
  • Peoples Educational Holdings Inc. PEDH (2)
  • Perf Go Green Holdings Inc. PGOG (12)
  • Perfect Web Technologies, Inc PWBI (11)
  • Perfectenergy International Ltd. PFGY (1)
  • Performance Health Technologies Inc. PFMH (31)
  • Pet DRX Corp. VETS (1)
  • Petro Resources Corp. PRC (2)
  • Petrogress, Inc. PGAS (2)
  • PetroSun Inc. PSUD (41)
  • Petroteq Energy Inc. PQEFF (11)
  • Phantom Fiber Corp. PHFB (2)
  • Pilot Financial Communications (3)
  • Pipex Pharmaceuticals Inc. PP (2)
  • PITOOEY! Inc. PTOO (14)
  • Planet Nutrition Inc. PNHL (4)
  • Platina Energy Group Inc. PLTG (8)
  • PlayBOX Inc. PYBX (5)
  • Players Network PNTV (15)
  • Pluristem Therapeutics Inc. PSTI (10)
  • Positron Corp. POSC (3)
  • PotNetwork Holding, Inc. POTN (27)
  • Power of the Dream Ventures (1)
  • Power Play Development Corp. PWPY (17)
  • Powersafe Technology Corp. PWSF (1)
  • Premier Energy Corp. PNRC (1)
  • Pressure BioSciences Inc. PBIO (41)
  • PRG Group Inc. PRGJ (2)
  • PrimEdge Inc. PEDI (1)
  • Private Equity Securities (93)
  • Pro Motors Group Corp. PMGU (2)
  • Pro Travel Network Inc. PTVL (2)
  • ProBility Media Corp. PBYA (33)
  • ProGaming Platforms Corp. PPTF (22)
  • Proginet Corp. PRGF (3)
  • Prom Resources PRMO (9)
  • Propalms Inc. PRPM (3)
  • Provectus Pharmaceuticals Inc. PVCT (12)
  • Puget Technologies Inc. PUGE (23)
  • Pulmo BioTech Inc. PLMO (4)
  • Puramed Bioscience Inc. PMBS (3)
  • Pure Biofuels Corp. PBOF (4)
  • Pure H2O Inc. PURH (1)
  • Pure Hospitality Solutions Inc. PNOW (99)
  • Purio Inc. PURO (5)
  • Puritan Financial Group Inc. PTNG (1)
  • Purple Beverage Company Inc. PPBV (8)
  • QED Connect Inc. QEDC (4)
  • Qiao Xing Universal Telephone Inc. XING (2)
  • QPC Lasers Inc. QPCI (3)
  • Qualcomm Inc. QCOM (2)
  • QualityStocks for Women (16)
  • QualityStocks Partner StockGuru (3,878)
  • QualityStocks Stock Newsletter (551)
  • QualityStocks Stock Newsletters (18,172)
  • QualityStocks Video Charts (286)
  • QualityStocks.net Market Basics (6)
  • QualityStocksNewsBreaks (414)
  • Quantum Fuel Systems Technologies Worldwide Inc. QTWW (15)
  • Quantum International Corp. QUAN (3)
  • Quasar Aerospace Industries Inc. QASP (6)
  • QuoteMedia Inc. QMCI (120)
  • Rafarma Pharmaceuticals Inc. RAFA (31)
  • Rainbow Coral Corp. RBCC (33)
  • Rancher Energy Corp. RNCH (9)
  • Raptor Resources Holdings Inc. RRHI (50)
  • Raven Gold Corp. RVNG (3)
  • Red Lake Exploration Inc. RLKX (19)
  • RegalWorks Media Inc. RWMI (4)
  • Regenicin, Inc. RGIN (6)
  • Reliant Financial Services Inc. RFNS (1)
  • Renhuang Pharmaceuticals Inc. RHGP (3)
  • ReoStar Energy Corp. REOS (1)
  • Resort Savers Inc. (RSSV) (10)
  • Revett Minerals (1)
  • RJD Green Inc. RJDG (13)
  • Rock Energy Resources Inc. RCKE (4)
  • Rodman & Renshaw (432)
  • Ronn Motor Company Inc. RNNM (6)
  • Rox Resources Ltd. RXRS (3)
  • Royal Quantum Group, Inc. RYQG (10)
  • Royal Standard Minerals Inc. RYSMF (2)
  • Rudy Nutrition RUNU (27)
  • RXi Pharmaceuticals Corp. RXII (3)
  • Santa Fe Gold Corp. SFEG (5)
  • Santa Fe Holding Company SFHD (3)
  • Save The World Air Inc. ZERO (12)
  • Savoy Energy Corp. SNVP (26)
  • SavWatt USA, Inc. SAVW (5)
  • Seabridge Gold Inc. SA (1)
  • Seawright Holdings Inc. SWRI (1)
  • Sector 10 Inc. SECI (78)
  • SES Solar Inc. SESI (2)
  • Seven Arts Pictures plc SAPX (1)
  • Seven Arts Pictures PLC SAPXF (5)
  • Shazam Stocks (22)
  • ShotPak Inc. SHTP (35)
  • Shumate Industries SHMTE (1)
  • Sibling Group Holdings Inc. SIBE (55)
  • Sierra Gold Corp. SGCP (2)
  • Signature Devices Inc. SDVI (9)
  • Silver Dragon Resources Inc. SDRG (1)
  • Silver Falcon Mining Inc. SFMI (1)
  • SilverSun Technologies Inc. SSNT (30)
  • Simtrol Inc. SMRL (74)
  • Simulated Environment Concepts Inc. SMEV (130)
  • Singlepoint Inc. SING (117)
  • Sino Agro Food Inc. SIAF (1)
  • Sinobiomed Inc. SOBM (4)
  • Sinovac Biotech Ltd SVC (1)
  • Sipp Industries Inc. SIPC (2)
  • Skinny Nutritional Corp. SKNY (19)
  • Skinvisible, Inc. SKVI (16)
  • Sky Petroleum Inc. SKPI (1)
  • SkyPostal Networks Inc. SKPN (66)
  • Small Cap Sentinel (2)
  • Small Cap Sleeper (3)
  • Smallcap Bullets (2)
  • Smallcaps.us (22)
  • SmallCapVoice (428)
  • Smoky Market Foods Inc. SMKY (9)
  • SocialPicks (1)
  • Sofame Technologies Inc SDW.V (1)
  • Sohm Inc. SHMN (14)
  • Solanex Management Inc. SLNX (15)
  • Solar Energy Initiatives Inc. SNRY (14)
  • Solar Wind Energy Tower Inc. SWET (15)
  • Solarfun Power Holdings Co. Ltd. SOLF (2)
  • Soul and Vibe Interactive Inc. SOUL (14)
  • South Sea Energy Corp. SSGY (7)
  • Soyo Group Inc SOYO (2)
  • SpaceDev Inc. SPDV (5)
  • Sparta Commercial Services Inc. SRCO (31)
  • Speedemissions Inc. SPMI (14)
  • Spicy Pickle Inc SPKL (18)
  • SpongeTech Delivery Systems Inc. SPNG (14)
  • Sports Pouch Beverage Company Inc. SPBV (1)
  • Star Mountain Resources Inc. SMRS (37)
  • Start Scientific Inc. STSC (22)
  • Stealth Technologies, Inc. STTH (3)
  • Stock Market E-News (1)
  • Stock Promoters (4)
  • StockEgg (14)
  • Stocks to Watch (1,929)
  • StocksJournal (2)
  • StockUPTicks (165)
  • Stockwire (6)
  • Strategic American Oil Corp SGCA (32)
  • Stratos Renewables Corp. SRNW (89)
  • StreamTrack Inc. STTK (31)
  • Striker Oil & Gas Inc. SOIS (4)
  • Sun Motor International Inc. SNMO (1)
  • SUN Sports & Entertainment Inc. SSPE (3)
  • Sunshine Biopharma Inc. SBFM (6)
  • Superlattice Power Inc. SLAT (60)
  • SupportSave Solutions, Inc. SSVE (10)
  • Surefect Holdings Inc. SUFH (1)
  • Suspect Detection Systems Inc. SDSS (37)
  • Sweet Success Enterprises Inc. SWTS (35)
  • Swiss Hawk AG SWHKF (1)
  • Symposium Production Corp. SYPJ (1)
  • Tactical Air Defense Services, Inc. TADF (15)
  • Tao Minerals Ltd. TAOL (1)
  • TapImmune, Inc. TPIV (15)
  • Tapinator, Inc. TAPM (14)
  • Taplmmune Inc. TPIM (1)
  • Technology Applications International Inc. NUUU (25)
  • TechPrecision Corp. TPCS (4)
  • Tecton Corp. TTNC (3)
  • Teknik Digital Arts Inc. TKNK (10)
  • Telanetix Inc. TNXI (2)
  • Teletouch Communications Inc. TLLE (5)
  • Terax Energy Inc. TEXG (32)
  • Terme Bancorp TMEB (1)
  • Terra Nostra Resources Corp. TNRO (25)
  • The Amergence Group AMNG (8)
  • The Aristocrat Group Corp. ASCC (113)
  • The Bowser Report (68)
  • The Bull Report (32)
  • The Capital Report (5)
  • The DIRECTV Group Inc. DTV (1)
  • The Fight Zone Inc. TFZI (12)
  • The Green Organic Dutchman Holdings Ltd. TGOD (3)
  • The Guitammer Company Inc. GTMM (38)
  • The International Traders Expo (30)
  • The Mobile Star Corp. MBST (7)
  • The Motley Fool (3)
  • The Mundus Group Inc. MNDS (1)
  • The Penny Stock Blog (28)
  • The Principal Structure Fund, Inc. PSF (2)
  • The Tracking Corp. TRKG (1)
  • The UpTurn, Inc. UPTR (20)
  • The Wall Street Savant (24)
  • The Wide Angle (3)
  • Thresher Industries Inc. THRR (15)
  • Tidelands Oil and Gas Corp. TIDE (1)
  • Tiens Biotech Group USA Inc. TBV (1)
  • TMT Capital Corp. TMTP (1)
  • TNI BioTech Inc. TNIB (16)
  • Tombstone Exploration Corp. TMBXF (9)
  • TOMI Environmental Solutions Inc. TOMZ (4)
  • Tootie Pie Company, Inc. TOOT (11)
  • Torchlight Energy Resources, Inc. TRCH (2)
  • TradeShow Marketing Company Inc. TSHO (21)
  • TransWorldNews (4)
  • Tri-Star Holdings Inc. TSHL (31)
  • Trimax Corp. TMXN (31)
  • TripleCrownStocks (9)
  • True 2 Beauty Inc. TRTB (43)
  • TwinTrader (8)
  • TXP Corporation TXPO (1)
  • TZ Ltd. TZL.AX (1)
  • U.S. Mine Makers Inc. USMM (1)
  • uKarma Corporation UKMA (1)
  • Ultitek Ltd. UITK (21)
  • Unbridled Energy Corporation TSX-UNE (21)
  • Unico Inc. UNCO (3)
  • Universal Bioenergy Inc. UBRG (3)
  • Universal Detection Technology UNDT (41)
  • Universal Energy Corp. UVSE (19)
  • Universal Property Development and Acquisition UPDA (4)
  • Universal Tracking Solutions Inc. UTRK (13)
  • Universal Travel Group UTVG (14)
  • UpSNAP Inc. UPSN (1)
  • Uranium Energy Corp. UEC (64)
  • Uranium Hunter Corp. URHN (17)
  • Urex Energy Corp. URXE (1)
  • USA Recycling Industries Inc. USRI (21)
  • USA Superior Energy Inc. USSU (9)
  • Ustelematics Inc. UTLM (27)
  • Utah Uranium Corp. UTUC (2)
  • Utilicraft Aerospace Industries Inc. UITA (2)
  • ValueRich & iValueRich (9)
  • Vaporin Inc. VAPOD (2)
  • VentriPoint Diagnostics Ltd. VPTDF (26)
  • Veritas Pharma Inc. VRTHF (6)
  • Vermillion Inc. VRML (3)
  • Vertical Branding Inc. VBDG (11)
  • VIASPACE, Inc. VSPC (185)
  • Victory Energy Corp. VYEY (29)
  • Victory Square Technologies Inc. VSQTF (2)
  • Vidshadow Inc. VSHD (1)
  • View Systems Inc. VSYM (16)
  • Viper Networks Inc. VPER (2)
  • Viral Genetics Inc. VRAL (3)
  • Viropro International Inc. VPRO (2)
  • VirTra Systems Inc. VTSI (22)
  • Viscount Systems Inc. VSYS (27)
  • visionGATEWAY Inc. VGWA (1)
  • VistaGen Therapeutics Inc. VSTA (104)
  • Visualant Inc. VSUL (5)
  • Vital Products Inc. VTLP (5)
  • Viyya Technologies Inc. VYON (2)
  • VizStar Inc VIZS (24)
  • Voiceserve Inc. VSRV (18)
  • Vortex Resources Corp. VTEX (7)
  • Vsurance Inc. VSUR (3)
  • Vyteris Inc. VYHN (1)
  • W2 Energy Inc. WWEN (13)
  • Wall Street News Alert (76)
  • WallStreetGrapevine (12)
  • WaterPure International Inc. WPUR (4)
  • Wave Systems Corp. WAVX (5)
  • Week in Review (2)
  • Well Power Inc. WPWR (77)
  • Wescorp Energy Inc. WSCE (18)
  • West Canyon Energy Corp. WCYO (1)
  • Western Standard Energy Corp. WSEG (7)
  • Who's Your Daddy Inc. WYDI (7)
  • WikiLoan Inc. WKLI (14)
  • Wind Energy America Inc. WNEA (3)
  • Wisdom Homes of America Inc. WOFA (15)
  • Wits Basin Precious Minerals Inc. WITM (2)
  • Woize International Ltd. WOIZ (1)
  • WordLogic Corp. WLGC (40)
  • Workstream Inc. WSTM (9)
  • WorldWater & Solar Technologies Corp. WWAT (10)
  • Worldwide Energy and Manufacturing WEMU (12)
  • Worldwide Manufacturing USA Inc. WWMU (6)
  • WRIT Media Group Inc. WRIT (36)
  • X-Change Corp. (XCHC) (2)
  • Xaar Plc XAARF (1)
  • Xenomics Inc. XNOM (1)
  • XsunX Inc. XSNX (17)
  • XZERES Corp. XPWR (2)
  • Younger America YNGR (13)
  • Zacks Investment Research (11)
  • ZAGG Inc. ZAGG (9)
  • Zaldiva Inc. ZLDV (3)
  • ZAP ZAAP (15)
  • ZBB Energy Corp ZBB (7)
  • Zenosense Inc. ZENO (53)
  • Zentric Inc. ZNTR (14)
  • Zevotek Inc. ZVTK (8)
  • Zinc One Resources Inc. ZZZOF (6)
  • Znomics Inc. ZNOM (3)
  • Newsletter Signup

    Stay ahead of the pack with QualityStocks and receive "The QualityStocks Daily", our summary formatted newsletter containing stock tips from hundreds of online investment newsletters.

    Rotate your device 90° to view site.